Robin Foà

25PUBLICATIONS
115CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsiesOrthopaedicsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jan 22, 2026
Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.

Michela Ansuinelli, Nadia Peragine, Maria Stefania De Propris

|Jul 08, 2025
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma.

Riccardo Dondolin, Federico Garrou, Mohammad Almasri

|Jun 02, 2025
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study.

Gianluca Cavallaro, Davide Lazzarotto, Chiara Pavoni

|Dec 21, 2023
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.

Robin Foà, Renato Bassan, Loredana Elia

|Sep 13, 2023
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.

Darina Ocadlikova, Federico Lussana, Nicola Fracchiolla

|Aug 15, 2023
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.

Riccardo Moia, Lodovico Terzi di Bergamo, Donatella Talotta

Pageof 5

Frequent Collaborators

4 joint publications

Federico Lussana

4 joint publications

Massimiliano Bonifacio

4 joint publications

Sabina Chiaretti

3 joint publications

Paolo Ghia